Medication info

Peripure 1.5% Solution

Prescription medicationSolutionInjection
Ingredient · strength
Glucose Hydrate›41.25gCalcium Chloride Hydrate›0.507gMagnesium Chloride›0.14gSodium Chloride›8.43gSodium Bicarbonate›3.29gSodium Lactate 60%›4.38g
Manufacturer / importer
Boryeong Biopharma Co., Ltd.
Appearance
This medication is a pale yellow transparent peritoneal dialysis solution contained in a colorless transparent plastic bag with two chambers.
Packaging
2L/bag (A solution:B solution = 725:1275), 3L/bag (A solution:B solution=1087.5:1912.5)
Approval status
Active

MFDS item code 201606583 · Notified 2016.11.10 · Insurance code 670500911,670500912

Summary

Main use
Peritoneal dialysis for renal failure, detoxification in drug poisoning, and relief of discomfort caused by lactate-based dialysate
Who receives it
Adults
Adult administration
1. The attending physician should adjust the treatment regimen, number of exchanges, exchange volume, dialysis time, and duration according to the patient's condition. 2. Use as a solution for intraperitoneal administration for dialysis treatment. 3. The dose varies according to body size, and the frequency of solution exchanges should be appropriately adjusted based on biochemical parameters and fluid balance. In general, 1.5 ~ 2.5L is infused into the peritoneal cavity per exchange in adults. For continuous ambulatory peritoneal dialysis, perform drainage after a 4 ~ 8-hour dwell, 3 ~ 5 times daily; for automated peritoneal dialysis, perform 4 ~ 5 cycles overnight using a machine and up to 2 cycles during the day. 4. When a machine is used intermittently or continuously for peritoneal dialysis, it is preferable to use a bag with a volume greater than the machine's exchange volume. 5. The glucose concentration should be selected according to the patient's ultrafiltration requirements and kept as low as possible.

Ingredients

Manufacturer
Boryeong Biopharma Co., Ltd.

Efficacy & effects

Peritoneal dialysis for renal failure, detoxification in drug poisoning, and relief of discomfort caused by lactate-based dialysate

  • Acute and chronic renal failure
  • drug overdose
  • discomfort due to low pH
View approved original text

This medicine is a dialysis solution used for peritoneal dialysis in patients with acute and chronic renal failure. It also helps detoxify patients suffering from drug overdose when other treatments are ineffective. Additionally, it alleviates discomfort that may arise from low pH when using a dialysis solution composed solely of lactic acid. Therefore, this drug is used to treat renal failure patients and improve discomfort during dialysis.

How it is given

Adult administration

1. The attending physician should adjust the treatment regimen, number of exchanges, exchange volume, dialysis time, and duration according to the patient's condition. 2. Use as a solution for intraperitoneal administration for dialysis treatment. 3. The dose varies according to body size, and the frequency of solution exchanges should be appropriately adjusted based on biochemical parameters and fluid balance. In general, 1.5 ~ 2.5L is infused into the peritoneal cavity per exchange in adults. For continuous ambulatory peritoneal dialysis, perform drainage after a 4 ~ 8-hour dwell, 3 ~ 5 times daily; for automated peritoneal dialysis, perform 4 ~ 5 cycles overnight using a machine and up to 2 cycles during the day. 4. When a machine is used intermittently or continuously for peritoneal dialysis, it is preferable to use a bag with a volume greater than the machine's exchange volume. 5. The glucose concentration should be selected according to the patient's ultrafiltration requirements and kept as low as possible.

Precautions

This drug is used for peritoneal dialysis, and abruptly stopping peritoneal dialysis can pose a life-threatening risk if no other renal replacement therapy is undertaken. It should not be used in patients with specific conditions such as diaphragmatic defects, severe abdominal burns or inflammation, and severe peritoneal adhesions. Additionally, it should not be administered to patients suspecting lactic acidosis, severe hypokalemia, recent abdominal surgery, inflammatory bowel disease, or those with abdominal fistulas. This drug must also not be used in patients with mental or physical conditions that prevent peritoneal dialysis. Patients taking digitalis preparations, those suspected of having carbohydrate metabolism disorders, lumbar spine disorders, or patients taking diuretics should have their blood electrolytes and glucose levels checked periodically when using this medication. Local pain or bleeding at the injection site, peritonitis, nausea, abdominal pain, diarrhea, electrolyte imbalances, hypercholesterolemia, and dyspnea may occur as various adverse reactions. Fluid balance must be carefully managed during peritoneal dialysis, and the procedure must be conducted in a sterile environment to prevent infections. Prior to administration, the state of the dialysis solution should be thoroughly checked, and factors such as weight, nutritional status, and blood test results should be monitored regularly during use. Special precautions are necessary for pregnant or breastfeeding women, children, and the elderly, with dose adjustments for children. Overdosage may result in dehydration, electrolyte disturbances, and hyperglycemia, necessitating caution and immediate consultation with healthcare professionals if adverse symptoms appear. Peritoneal dialysis solutions should be used without opening the provided container, and should not be used if there are signs of defects in the container or liquid. Drugs should always be added in a sterile manner before use, and any remaining liquid should be discarded after use, while storage must avoid direct sunlight or freezing. This drug is known not to affect driving or machine operation abilities.

Side effects

Abdominal pain, bleeding, peritonitis, turbid discharge, fever, inflammation around the abdominal catheter, redness, discharge, catheter breakage, drainage difficulties, subcutaneous inflammation, nausea, abdominal pain, diarrhea, constipation, hemorrhoids, vomiting, loss of appetite, abdominal bloating, intestinal obstruction, hypokalemia, hyponatremia, hypocalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, metabolic acidosis, hypoproteinemia, hyperglycemia, dyspnea due to diaphragm elevation, pulmonary edema, pleural effusion, secondary hyperparathyroidism, edema, amino acid loss, water-soluble vitamin loss, shoulder pain, muscle cramps, hernia, hydrocele, obesity, weakness, syncope, fatigue, headache, dizziness, tachycardia, hypertension, hypotension, sclerosing encapsulating peritonitis, sepsis

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent contact with air. Additionally, it must not be frozen and should be kept in a cool place below 25 degrees Celsius.

Appearance and packaging

Appearance

This medication is a pale yellow transparent peritoneal dialysis solution contained in a colorless transparent plastic bag with two chambers.

Package unit

2L/bag (A solution:B solution = 725:1275), 3L/bag (A solution:B solution=1087.5:1912.5)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.